MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer

Chuntao Wang, Yanliang Liu, Wenyi Guo, Xu Zhu, Nita Ahuja, Tao Fu

Research output: Contribution to journalArticle

Abstract

Background: The methylation of microtubule-associated protein tau (MAPT) was first described in patients with Alzheimer’s disease. In this study, we aim to determine if MAPT promoter CpG island is hypermethylated and whether this signature could work as a prognostic marker for patients with stage II colorectal cancer (CRC). Methods: MAPT methylation level and CpG island methylator phenotype (CIMP) status were examined. The prognostic value of MAPT methylation was analyzed using Cox regression analysis. Results: Amongst stage II CRC patients (n=107), hypermethylation of MAPT promoter CpG island was seen in 23.4% of them. MAPT methylation was much more frequent in patients with age ≥60 compared to age <60 (P<0.001). MAPT were preferentially methylated among proximal colon tumors or CIMP high tumors (both P<0.001). Five-year overall survival (OS) rates were 57.1% and 79.4% for patients with and without MAPT hypermethylation, respectively, HR=2.33 (95% CI, 1.19–4.57; P=0.014). MAPT hypermethylation remained an important prognostic variable for OS in multivariate analysis with a HR of 2.29 (95% CI, 1.01–5.18; P=0.047). Conclusion: Our findings suggest that MAPT is frequently methylated and hypermethylation is associated with worse prognosis in patients with stage II CRC.

Original languageEnglish (US)
Pages (from-to)7337-7343
Number of pages7
JournalCancer Management and Research
Volume11
DOIs
StatePublished - Jan 1 2019

Fingerprint

CpG Islands
Microtubule-Associated Proteins
Colorectal Neoplasms
Methylation
Phenotype
Neoplasms
Alzheimer Disease
Colon
Multivariate Analysis
Survival Rate
Regression Analysis

Keywords

  • Colorectal cancer
  • MAPT
  • Methylation
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer. / Wang, Chuntao; Liu, Yanliang; Guo, Wenyi; Zhu, Xu; Ahuja, Nita; Fu, Tao.

In: Cancer Management and Research, Vol. 11, 01.01.2019, p. 7337-7343.

Research output: Contribution to journalArticle

@article{fb70d1c0a6a94e6396b7a4946623bad7,
title = "MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer",
abstract = "Background: The methylation of microtubule-associated protein tau (MAPT) was first described in patients with Alzheimer’s disease. In this study, we aim to determine if MAPT promoter CpG island is hypermethylated and whether this signature could work as a prognostic marker for patients with stage II colorectal cancer (CRC). Methods: MAPT methylation level and CpG island methylator phenotype (CIMP) status were examined. The prognostic value of MAPT methylation was analyzed using Cox regression analysis. Results: Amongst stage II CRC patients (n=107), hypermethylation of MAPT promoter CpG island was seen in 23.4{\%} of them. MAPT methylation was much more frequent in patients with age ≥60 compared to age <60 (P<0.001). MAPT were preferentially methylated among proximal colon tumors or CIMP high tumors (both P<0.001). Five-year overall survival (OS) rates were 57.1{\%} and 79.4{\%} for patients with and without MAPT hypermethylation, respectively, HR=2.33 (95{\%} CI, 1.19–4.57; P=0.014). MAPT hypermethylation remained an important prognostic variable for OS in multivariate analysis with a HR of 2.29 (95{\%} CI, 1.01–5.18; P=0.047). Conclusion: Our findings suggest that MAPT is frequently methylated and hypermethylation is associated with worse prognosis in patients with stage II CRC.",
keywords = "Colorectal cancer, MAPT, Methylation, Prognosis",
author = "Chuntao Wang and Yanliang Liu and Wenyi Guo and Xu Zhu and Nita Ahuja and Tao Fu",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/CMAR.S206731",
language = "English (US)",
volume = "11",
pages = "7337--7343",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer

AU - Wang, Chuntao

AU - Liu, Yanliang

AU - Guo, Wenyi

AU - Zhu, Xu

AU - Ahuja, Nita

AU - Fu, Tao

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The methylation of microtubule-associated protein tau (MAPT) was first described in patients with Alzheimer’s disease. In this study, we aim to determine if MAPT promoter CpG island is hypermethylated and whether this signature could work as a prognostic marker for patients with stage II colorectal cancer (CRC). Methods: MAPT methylation level and CpG island methylator phenotype (CIMP) status were examined. The prognostic value of MAPT methylation was analyzed using Cox regression analysis. Results: Amongst stage II CRC patients (n=107), hypermethylation of MAPT promoter CpG island was seen in 23.4% of them. MAPT methylation was much more frequent in patients with age ≥60 compared to age <60 (P<0.001). MAPT were preferentially methylated among proximal colon tumors or CIMP high tumors (both P<0.001). Five-year overall survival (OS) rates were 57.1% and 79.4% for patients with and without MAPT hypermethylation, respectively, HR=2.33 (95% CI, 1.19–4.57; P=0.014). MAPT hypermethylation remained an important prognostic variable for OS in multivariate analysis with a HR of 2.29 (95% CI, 1.01–5.18; P=0.047). Conclusion: Our findings suggest that MAPT is frequently methylated and hypermethylation is associated with worse prognosis in patients with stage II CRC.

AB - Background: The methylation of microtubule-associated protein tau (MAPT) was first described in patients with Alzheimer’s disease. In this study, we aim to determine if MAPT promoter CpG island is hypermethylated and whether this signature could work as a prognostic marker for patients with stage II colorectal cancer (CRC). Methods: MAPT methylation level and CpG island methylator phenotype (CIMP) status were examined. The prognostic value of MAPT methylation was analyzed using Cox regression analysis. Results: Amongst stage II CRC patients (n=107), hypermethylation of MAPT promoter CpG island was seen in 23.4% of them. MAPT methylation was much more frequent in patients with age ≥60 compared to age <60 (P<0.001). MAPT were preferentially methylated among proximal colon tumors or CIMP high tumors (both P<0.001). Five-year overall survival (OS) rates were 57.1% and 79.4% for patients with and without MAPT hypermethylation, respectively, HR=2.33 (95% CI, 1.19–4.57; P=0.014). MAPT hypermethylation remained an important prognostic variable for OS in multivariate analysis with a HR of 2.29 (95% CI, 1.01–5.18; P=0.047). Conclusion: Our findings suggest that MAPT is frequently methylated and hypermethylation is associated with worse prognosis in patients with stage II CRC.

KW - Colorectal cancer

KW - MAPT

KW - Methylation

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85070797507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070797507&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S206731

DO - 10.2147/CMAR.S206731

M3 - Article

VL - 11

SP - 7337

EP - 7343

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -